Arcadis: Further in German rail. CVC Capital Partners: They beat, they score. D'Ieteren: US Belron peer Boyd 4Q24 a bit ahead, weak 2025 early outlook. Fastned: Preview FY24. IBA: 2H24 better REBIT, net cash but outlook on the low side. Proximus: Interim leadership announced. UCB: Peer Immunovant reports mixed results in gMG Zabka: Peer Jeronimo Martins FY24 results
UCB presented results from studies involving doxecitine (dC) and doxribtimine (dT) (pyrimidine nucleoside therapy) in people living with thymidine kinase 2 deficiency (TK2d), at the MDA Clinical and Scientific Conference, being held 16-19 March in Dallas. The improvements in survival and functional outcomes highlight the potential of doxecitine and doxribtimine in treating TK2d, which is an ultra-rare genetic mitochondrial disease with no approved therapies, and has a prevalence of 1.64/1m peopl...
At the American Academy of Dermatology (AAD) 2025 conference, UCB presented strong 5-year follow-up data for Bimzelx in plaque psoriasis and 2-year follow-up in hidradenitis suppurativa. Meanwhile, Johnson & Johnson also announced Phase 3 data for its oral drug icotrokinra in psoriasis, showing promising results and planning further trials. In addition, Amgen reported positive Phase 3 results for rocatinlimab in atopic dermatitis. These developments highlight significant advancements in dermatol...
Additional data presented at AAD 2025 further cement Bimzelx' leadership in the IL-17 space for PsO and HS. In PsO, efficacy was well maintained from previous 4-year data into the 5-year follow-up with 67.7% PASI100 and 84.9% PASI90. In HS, additional 2-year data saw 55.7% pts with draining tunnels at baseline, a particularly painful manifestation, reaching clearance after two years. We reiterate our confidence in Bimzelx as an rising leader in the dermatology/rheumatology space, and confirm our...
We reiterate our BUY rating on UCB and increase our target price from €212 to €220 on the back of a slight increase in Bimzelx's long-term peak sales and Evenity, which is now profitable in Europe. We continue to view UCB's risk/reward balance as favourable, with the group pipeline accounting for only 6% of Enterprise Value. This allows UCB to have a decade-plus visibility on top- and bottom-line growth, in our view. We believe UCB offers growth at a reasonable valuation, the company now trading...
Aalberts: Dividend and outlook better than expected. Ackermans & van Haaren: Anticipating an all-time-high result from core segments. Ageas: FY24 in line, strong capital, outlook for upsteams. AMG: Strong 4Q24 beat and 2025F guidance upgrade. CFE: Solid results and balance sheet, outlook weak. CMB.TECH: Cautious on outlook. Corbion: Not so sweet. CTP: Good results, 2025 outlook realistic. D'Ieteren: Boyd's Five-Year Goals. Exor: Ferrari €3bn ABB and €1bn SBB. Sofina: Further ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.